Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients
10.3346/jkms.2024.39.e224
- Author:
Hyeon Mu JANG
1
;
Seongman BAE
;
Jiwon JUNG
;
Hyungwoo CHO
;
Dok Hyun YOON
;
Sung-Han KIM
Author Information
1. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- Publication Type:Brief Communication
- From:Journal of Korean Medical Science
2024;39(28):e224-
- CountryRepublic of Korea
- Language:English
-
Abstract:
The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1–2 years after transplant (median, 11 months; interquartile range, 9–14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], P = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT.
